Base de dados : HANSEN
Pesquisa : DAPSONA/ADMIN [Descritor de assunto]
Referências encontradas : 41 [refinar]
Mostrando: 1 .. 20   no formato [Detalhado]

página 1 de 3 ir para página          

  1 / 41 HANSEN  
              next record last record
seleciona
para imprimir
Texto Completo-en
Id:27120
Autor:Katoch, Kiran; Ramanathan, Usha; Natrajan, Mohan; Bagga, Ashok K; Bhatia, AS; Saxena, RK; Ramu, Gopal.
Título:Relapses in paucibacillary patients after treatment with three short term regimens containing rifampin.
Fonte:Int J Lepr;57(2):458-464, June 1989. ^btab.
Resumo:Three multidrug regimens all containing rifampin and dapsone have been tried for the treatment of 278 cases of paucibacillary leprosy. Regimen I was the one recommended by the WHO Study Group. Regimen II was the same as Regimen I with depsone alone continued for a further 6 months. Regimen III was the same as Regimen II but rifampin was given daily for the first 7 days. The patients were comparable with regard to disease classification, lepromin status, bacteriological status, and number of lesions. As reported earlier, the disease inactivity rates by 1 year of treatment were much greater with Regimens II and III than with Regimen I (94% and 97% vs 76%). Early reaction was seen in 6% of those in Regimen III and in none in Regimens I and II. Late reaction was observed in 9% of those in Regimen I and none in Regimens II and III. During 3 1/2 years of follow up, 13% of the cases in Regimen I, 1% in Regimen II, and 2% in Regimen III relapsed. Since the patients in the three regimens were otherwise comparable, it is concluded that the high inactivity rate, low relapse rate (1%-2%), and no early or late reaction as observed in Regimen II patients were because of adequate treatment^ien.
Descritores:Dapsona/admin
Dapsona/uso terap
Rifampina/admin
Rifampina/uso terap
Hanseníase/microbiol
Hanseníase/patol
Limites:Humanos
Masculino
Feminino
Adulto
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a02.pdf - en.
Localização:Br191.1


  2 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Texto Completo-en
Id:27119
Autor:Katoch, Kiran; Ramu, Gopal; Ramanathan, Usha; Sengupta, Utpal; Sharma, Vishnu D; Shivannavar, Channappa T; Katoch, Vishwa M.
Título:Results of a modified WHO regimen in highly bacilliferous BL/LL patients.
Fonte:Int J Lepr;57(2):451-457, June 1989. ^bgraf, ^btab.
Resumo: regimen consisting of 600 mg of rifampin once a month, 100 mg of clofazimine on alternate days, and 100 mg of dapsone daily was used in 56 untreated, highly bacillated borderline lepromatous/lepromatous (BL/LL) patients with an average bacterial index (BI) of 4.45. Treatment was continued until skin-smear negativity. After 2 years of therapy, none of the patients had become smear negative and the average BI was 2.56. There was no growth on inoculation of skin-tissue biopsies in the normal mouse foot pad after 6 months of therapy. Bacillemia was still detectable in 11/50 patients, and significant ATP levels were detected in Mycobacterium leprae from skin-tissue biopsies in 16% of the cases. After 3 years of therapy, three patients had become smear negative. The average BI was 1.30. None of the patients had detectable bacillemia, and 5% of the cases showed detectable ATP levels in M. leprae from tissue biopsies. After 4 years of therapy, 41.7% of the patients had become smear negative. The average BI was 0.66, and no ATP was detected in any of the purified bacillary suspensions. The fall in BI was accelerated, and more patients on continued treatment became negative earlier compared to those having treatment for a limited duration, as reported by others^ien.
Descritores:Clofazimina/admin
Clofazimina/uso terap
Dapsona/admin
Dapsona/uso terap
Hanseníase Dimorfa/microbiol
Hanseníase Virchowiana/microbiol
Limites:Humanos
Adolescente
Adulto
Meio Eletrônico:http://hansen.bvs.ilsl.br/textoc/revistas/intjlepr/1989/pdf/v57n2/v57n2a01.pdf - en.
Localização:Br191.1


  3 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:25376
Autor:Fasal, P
Título:Leprosy occurs everywhere
?-
Fonte:San Francisco; s.n; 1965. 7p p. ilus.
Resumo:Leprosy can occur at all ages, in both sexes and in every race. It can be found in any geographic area and can simulate many diseases, especially those affecting the skin. The lepromatous type indicates less host resistance than the tuberculoid type. Histopathologic examination of a properly stained specimen obtained by skin biopsy is the most important diagnostic procedure. Treatment consist of long-term chemotherapy with sulfone drugs.
Descritores:HANSENIASE/clas
HANSENIASE/compl
HANSENIASE/diag
HANSENIASE/epidemiol
HANSENIASE/imunol
HANSENIASE/terap
HANSENIASE/transm
HANSENIASE DIMORFA/diag
HANSENIASE TUBERCULOIDE/diag
HANSENIASE VIRCHOWIANA/diag
HANSENIASE/patol
DAPSONA/admin
DAPSONA/uso terap
DISTRIBUICAO ESPACIAL
 ANTIGENO DE MITSUDA/admin
 ANTIGENO DE MITSUDA/anal
 BIOPSIA/util
Limites:HUMANO
Localização:BR191.1; 00198/s


  4 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:25373
Autor:Gokhale, N. R; Sule, R. R; Gharpure, M. B
Título:Dapsone syndrome
..-
Fonte:s.l; s.n; 1992. 3p p. .
Descritores:DAPSONA/admin
DAPSONA/ef adv
DAPSONA/farmacol
DAPSONA/farmacocin
DAPSONA/tox
DAPSONA/uso terap
HANSENIASE/terap
 QUIMIOTERAPIA COMBINADA
Limites:HUMANO
Localização:BR191.1; 01165/s


  5 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18952
Autor:Murray, Clinton K; Joyce, M. Patricia; Longfield, Robert N
Título:Short report: treatment failure in Hanse´n's disease
..-
Fonte:s.l; s.n; 2003. 2 p. tab.
Resumo:Areas of low endemicity of Hansen's disease, such as Texas, California, and Hawaii, exist due to immigration and rare autochthonous infections. Managing this disease in these areas of low endemicity is difficult, especially in observing for relapse. The accurate diagnosis of relapse is imperative so that appropriate therapy can be promptly reinstituted and unnecessary treatment can be avoided. To assess treatment failures in an area of low endemicity, we retrospectively evaluated 113 patients with Hansen's disease treated in southern Texas. Of 57 patients who completed therapy, 11 were later restarted on medications for this disease for presumed relapse. However, nine of the 11 were found not to have true relapses of Hansen's disease. The accurate diagnosis of relapse of this disease is essential not only in the individual patient but also for prospective treatment trials to establish best practices. (AU).
Descritores:CLOFAZIMINA/admin
DAPSONA/admin
QUIMIOTERAPIA COMBINADA
HANSENIASE/quimioter
HANSENIASE/epidemiol
HANSENIASE/patol
HANSENIASE/prev
REGISTROS MEDICOS
RECIDIVA
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
TEXAS/epidemiol
FALHA DE TRATAMENTO
RECUSA DO PACIENTE AO TRATAMENTO
Limites:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 09084/s


  6 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18489
Autor:Goulart, Isabela Maria Bernades; Arbex, Guilherme Leonel; Carneiro, Marcus Hubaide; Rodrigues, Mariana Scalia; Gadia, Rafael
Título:Efeitos adversos da poliquimioterapia em pacientes com hanseníase: um levantamento de cinco anos em um Centro de Saúde da Universidade Federal de Uberlândia
Adverse effects of multidrug therapy in leprosy patients: a five-year survey at a Health Center of the Federal University of Uberlandia-
Fonte:s.l; s.n; set.-out. 2002. 8 p. tab.
Resumo:The introduction of multidrug therapy (WHO/MDT)-composed by the drugs dapsone, clofazimine and rifampicin has enabled the cure of Hansen's disease, however, the adverse effects of these drugs were not given priority by the health team. Aiming to determine MDT's adverse effects' magnitude and relate them to the non-adhesion of patients to the treatment, a study of 187 charts of patients treated with MDT from January of 1995 to May 2000, was carried out at a Health Center of the Federal University of Uberlandia. Side effects were recorded in 71 patients' charts. Among the 113 side effects found, 80 (70.7 per cent) were related to dapsone, 7 (6.2 per cent) were caused by rifampicin and 26 (20.5 per cent) were attributed to clofazimine. These effects induced 28 (14.9 per cent), patients to change the therapeutic scheme, representing 39.4 per cent from the 71 patients with adverse effects. Throughout this study, the importance is discussed of considering MDT's adverse effects when training the health team to heighten the patient's adhesion to the treatment and thereby collaborating to eliminate Hansen's disease as a public health problem. (AU).
Descritores:CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
DAPSONA/admin
DAPSONA/ef adv
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENIASE/quimioter
COOPERACAO DO PACIENTE/estatíst
DESISTÊNCIA DO PACIENTE/estatíst
ESTUDOS RETROSPECTIVOS
RIFAMPINA/admin
RIFAMPINA/ef adv
Limites:PRÉ-ESCOLAR
CRIANÇA
ADOLESCENCIA
ADULTO
RESUMO EM INGLES
FEMININO
HUMANO
LACTENTE
RECEM-NASCIDO
MASCULINO
MEIA-IDADE
Localização:BR191.1; 09017/s


  7 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18476
Autor:Queiroz, Regina Helena Costa; Souza, Ana Maria de; Sampaio, Suely Vilela; Melchior Junior, Enzo
Título:Biochemical and hematological side effects of clofazimine in leprosy patients
..-
Fonte:s.l; s.n; 2002. 4 p. tab.
Resumo:Gastrointestinal toxicity and red skin discoloration were the major side effects observed in leprosy patients undergoing long-term treatment with clofazimine (CFZ). Hematological and biochemical alterations have been cited among other side effects; however, their real magnitude and clinical significance at the doses currently employed in therapy have not been sufficiently documented. We therefore investigated the correlation between CFZ plasma concentration and biochemical (transaminases, bilirubins, alkaline phosphatase, gamma-glutamyltransferase, amylase, urea, creatinine, and potassium plasma levels) as well as hematological changes blood and reticulocyte counts, osmotic fragility, detection of Heinz bodies and methemoglobinemia (MHM), following in two regimes of treatment: CFZ as a single drug and CFZ as part of multidrug (MDT) therapy, in combination with dapsone and rifampicin. MHM and hemolytic anemia were detected in the MDT group only. Eosinophilia was found in patients of either group. Determination of hepatic, pancreatic and renal biochemical parameters showed rare, occasional changes of apparently no clinical significance. We conclude that CFZ is a generally well tolerated and safe drug when given as a daily dose of 50mg, which is currently used in leprosy patients. (AU).
Descritores:CONTAGEM DE CELULAS SANGUINEAS
CLOFAZIMINA/admin
CLOFAZIMINA/ef adv
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/ef adv
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
HANSENOSTATICOS/admin
HANSENOSTATICOS/ef adv
HANSENOSTATICOS/uso terap
HANSENIASE/sangue
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/ef adv
RIFAMPINA/uso terap
Limites:SUPPORT, NON-U.S. GOV'T
FEMININO
HUMANO
MASCULINO
Meio Eletrônico: - .
Localização:BR191.1; 08998/s


  8 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18448
Autor:Waters, M. F. R
Título:New approaches to chemotherapy for leprosy
..-
Fonte:s.l; s.n; dec. 1983. 3 p. .
Resumo:The treatment of leprosy with sulfones was introduced in 1943 and, perhaps surprisingly, drug resistance was not detected for many years. Proven dapsone resistance was first reported in 1964 by Pettit and Rees from the Sungei Buloh Leprosarium, Malaysia.(AU).
Descritores:QUIMIOTERAPIA COMBINADA
DAPSONA/admin
RIFAMPINA/admin
CLOFAZIMINA/admin
HANSENOSTATICOS/admin
HANSENIASE/quimioter
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 01651/s


  9 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18334
Autor:Waters, M. F. R
Título:New approaches to chemotherapy for leprosy
..-
Fonte:s.l; s.n; 1983. 3 p. .
Resumo:The treatment of leprosy with sulphones was introduced in 1943 and, perhaps surprisingly, drug resistance was not detected for many years. Proven dapsone resistance was first reported in 1964 by Pettit and Rees from the Sungei Buloh Lperosarium, Malaysia. (AU).
Descritores:HANSENIASE/quimioter
RIFAMPINA/admin
QUIMIOTERAPIA COMBINADA
CLOFAZIMINA/admin
HANSENOSTATICOS/admin
DAPSONA/admin
Limites:HUMANO
Localização:BR191.1; 04896/s


  10 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18299
Autor:Helander, I; Partanen, J
Título:Dapsone-induced distal axonal degeneration of the motor neurons
..-
Fonte:s.l; s.n; 1978. 4 p. .
Resumo:Dapsone proved to be effective treatment in a patient who suffered from erthema elevatum diutinum. Serious neurological side effects, however, appeared. The basic mechanism appeared to be a distal axonal degeneration of the motor neurons. Sensory conduction studies were normal in five consecutive EMG examinations. A diagnosis of anemia pernicosa was also made bu the blood values returned to normal after starting B12-vitamin therapy. Penicous anemia seemed not be an etiological factor in the polyneuropathy of our patient because we were not able toshow any damage to the sensory axons.(AU).
Descritores:POLINEUROPATIAS/ind quim
ERITEMA/quimioter
AXÔNIOS/ef drogas
NEURÔNIOS MOTORES/ef drogas
DEGENERACAO NEURAL
DAPSONA/admin
DAPSONA/ef adv
DAPSONA/uso terap
Limites:RELATO DE CASO
HUMANO
FEMININO
ADULTO
Meio Eletrônico: - .
Localização:BR191.1; 00351


  11 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18179
Autor:Shepard, Charles C; Walker, Laura L; Van Landingham, Rosalind M; Redus, Martha A
Título:Kinetic testing of drugs against Mycobacterium leprae in mice. Activity of cephaloridine, rifampin, streptovaricin, vadrine, and viomycin
..-
Fonte:s.l; s.n; jul. 1971. 5 p. tab, graf.
Resumo:A series of drugs that had been found active against Mycobacterium leprae in mice by the continous method of drug administration was tested by the kinetic method. Vadrine and vyomivin were found inactive. Cephaloridine, streptovaricin, and rifampin gave bactericidal-type results. In a second experiment, rifampin was found to have distinct bactericidal effect when given for only 2 days. The plasma levels of rifampin that were associated with bactericidal effect in mice were in the range reported for man receiving acceptable dosages of rifampin. Cephaloridine and, especially, rifampin merit further investigation in clinical trials in leprosy patients, either as single drugs or in combination with other active drugs. The combination of rifampin and dapsone (DDS) or acedapsone (DADDS) appear to provide the advantages of tboth drugs.(AU).
Descritores:ANTIMALARICOS/admin
DAPSONA/admin
INJECOES SUBCUTÂNEAS
HANSENIASE/quimioter
MYCOBACTERIUM LEPRAE/ef drogas
MYCOBACTERIUM LEPRAE/cresc
RIFAMPINA/admin
RIFAMPINA/sangue
VIOMICINA/admin
DIETA
 ESTUDOS DE AVALIACAO
 CINETICA
 MALARIA/sangue
 OXIDIAZOIS/admin
 PIRIDINAS/admin
 ACIDOS SALICILICOS/admin
 ESTREPTOVARICINA/admin
Limites:ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 02305/s


  12 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:18041
Autor:Shepard, Charles C; Levy, Louis; Fasal, Paul
Título:Further experience with the rapid bactericidal effect of rifampin on Mycobacterium leprae
..-
Fonte:s.l; s.n; nov. 1974. 5 p. tab, graf.
Resumo:The effect of rifampin therapy in leprosy was studied in two clinical short-term trials in which skin punch biopsy specimens were taken at regular intervals for the inoculation of mice in order to monitor the decrease in proportion of viable Mycobacterium leprae in the patients lesions. In a trial of rifampin in a dosage of 600mg daily, the bacterial viability feel to undectable levels in the first specimen taken after the start of theraphy (at 3-4 days in 4 patients, 7-8 days in 9, and 4 days in 2). Dapsone-treated controls required 20 to more than 112 days for the same change. In a trial of a single dose of 1,500mg rifampin, the viability fell to undetectable levels in the first specimen taken after the start of therapy also (at 3-5 days in all 14 patients).(AU).
Descritores:FATORES DE TEMPO
HANSENIASE/quimioter
MYCOBACTERIUM LEPRAE/ef drogas
DAPSONA/admin
DAPSONA/farmacol
ENSAIOS CLINICOS
RELACAO DOSE-RESPOSTA A DROGA
BIOPSIA
RIFAMPINA/admin
RIFAMPINA/farmacol
Limites:HUMANO
ANIMAL
CAMUNDONGOS
Meio Eletrônico: - .
Localização:BR191.1; 01966/s


  13 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17926
Autor:Fieldsteel, A. Howard; Levy, Louis
Título:Dapsone chemotherapy of Mycobacterium leprae infection of the neonatally thymectomized Lewis rat
..-
Fonte:s.l; s.n; nov. 1976. 6 p. tab.
Resumo:In order to learn whether the neonatally thymectomized Lewis rat (NTLR) infected with Mycobacterium leprae could serve as a model for chemotherapeutic studies in a situation resembling that found in human lepromatous leprosy, NTLR inoculated with M. leprae either locally or intravenously 9 to 16 months earlier were treated for from 1.5 to 8.5 months with dapsone (4,4´-diaminodiphenylsulfone, DDS) incorporated in the rat chow in the concentration providing the minimal inhibitory concentration of the drug for M. leprae and in the 100-fold larger concentration. NTLR were killed at intervals; the M. leprae were counted and passed to mice. Treatment with the smaller dosage of dapsone neither killed M. leprae nor reduced the number of organisms in the bacterial populations, whereas treatment with the larger dosage both killed M. leprae and reduced their numbers. The rate at which the organisms were killed (i.e., rendered noninfective for mice) was much the same as that in patients treated with dapsone in comparable dosage. The dead organisms were removed from the rat tissues at a faster rate than encountered in patients. The NTLR may indeed be suitable for chemotherapeutic studies relevant to man. In addition, the more rapid diappearance of dead M. leprae from the rat tissues may facilitate the study of treatment regimens designed to eradicate persisting viable organisms.(AU).
Descritores:ANIMAIS RECEM-NASCIDOS
DAPSONA/admin
MODELOS ANIMAIS DE DOENCAS
HANSENIASE/quimioter
HANSENIASE/parasitol
CAMUNDONGOS ENDOGÂMICOS BALB C
MYCOBACTERIUM LEPRAE
RATOS ENDOGÂMICOS LEW
RATOS DE CEPAS ENDOGÂMICAS
TIMECTOMIA
Limites:ANIMAL
MASCULINO
FEMININO
CAMUNDONGOS
RATOS
SUPPORT, U.S. GOV'T, P.H.S.
Meio Eletrônico: - .
Localização:BR191.1; 00545/s


  14 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17920
Autor:Prabhakaran, K; Harris, E. B; Kirchheimer, W. F
Título:A possible method for improving the efficacy of dapsone
..-
Fonte:s.l; s.n; December 15, 1980. 2 p. tab.
Resumo:The antileprosy drug dapsone is unable to penetrate intact Mycobacterium leprae in vitro, as determined by its effect on o-diphenoloxidase in the bacilli. When combined with the peptide polylysine, the sulfone drug passes through the bacterial cell membranes, and penetrates the enzyme protein, resulting in a 100% inhibition of its activity.
Descritores:CATECOL OXIDASE/antag
PERMEABILIDADE DA MEMBRANA CELULAR/ef drogas
COMBINACAO DE MEDICAMENTOS
CONCENTRACAO DE IONS DE HIDROGÊNIO
MYCOBACTERIUM LEPRAE/enzimol
PEPTIDIOS/uso terap
DAPSONA/admin
DAPSONA/farmacol
POLILISINA/farmacol
POLILISINA/uso terap
Meio Eletrônico: - .
Localização:BR191.1; 00684/s


  15 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17886
Autor:Taylor, P. M
Título:The clinical diagnosis of dapsone resistant leprosy
..-
Fonte:s.l; s.n; jan. 1982. 6 p. ilus.
Resumo:For the early recognition of dapsone resistance, it is essential to regularly examine patients at risk for suspicious new lesions, backed by regular clinical treatment records including smear results. The earlier the recognition and starting on alternative treatment, the better is the response. However, it is not advisable to change treatment without attempting at least clinical confirmation, and endorsing the chart so that the problem is not missed on subsequent occasions.(AU).
Descritores:RESISTÊNCIA MICROBIANA A DROGAS
PELE/patol
MYCOBACTERIUM LEPRAE/ef drogas
DAPSONA/admin
DAPSONA/farmacol
DAPSONA/uso terap
HANSENIASE/quimioter
HANSENIASE/patol
Limites:HUMANO
Meio Eletrônico: - .
Localização:BR191.1; 00913/s


  16 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17851
Autor:Dey, S. K; Chanda, M; Chowdhury, A; Panja, S. K
Título:Treatment of paucibacillary leprosy by WHO regimen
..-
Fonte:s.l; s.n; jan. 1987. 3 p. .
Resumo:50 Cases of paucibacillary leprosy was selected for study multi-drug therapy recommended by W.H.O. for sixth months. At the end of six months, 46 cases showed "no clinical activity" and 4 cases showed increased clinical activityweth flaring up of the lesions during treatment.(AU).
Descritores:DAPSONA/admin
DAPSONA/uso terap
COMBINACAO DE MEDICAMENTOS
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/uso terap
ORGANIZACAO MUNDIAL DA SAUDE
Limites:HUMANO
MASCULINO
FEMININO
CRIANÇA
ADULTO
MEIA-IDADE
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 02084/s


  17 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17839
Autor:Bourée, P; Carré, N; Drahmane, S
Título:Guinée: dépistage de la lèpre et traitement par polychimiothérapie
Guinea: detection of leprosy and treatment by polychemotherapy-
Fonte:s.l; s.n; 1988. 9 p. mapas, tab.
Resumo:Since a year, the implementation of multidrug therapy on leprosy control in Guinea has been needing a good cooperation between Department of Leprosy Control and local nurses. The known prevalence, in the area of Pita is 1.23%. 246 patients has been detected: 36 multibacillary and 210 paucibacillary. The sex-ratio of the patients has changed, during one year, toward the men. With the sensitivity of the local population, number of detected cases is increasing and the rate of regular attendance at treatment is correct in 87.6% of cases.(AU).
Descritores:HANSENIASE/quimioter
HANSENIASE/epidemiol
RIFAMPINA/admin
RIFAMPINA/uso terap
AFRICA OCIDENTAL
CLOFAZIMINA/admin
CLOFAZIMINA/uso terap
DAPSONA/admin
DAPSONA/uso terap
QUIMIOTERAPIA COMBINADA
Limites:HUMANO
MASCULINO
FEMININO
RESUMO EM INGLES
Meio Eletrônico: - .
Localização:BR191.1; 02055/s


  18 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17835
Autor:Pieters, F. A; Woonink, F; Zuidema, J
Título:Influence of once-monthly rifampicin and daily clofazimine on the pharmacokinetics of dapsone in leprosy patients in Nigeria
..-
Fonte:s.l; s.n; 1988. 4 p. tab, graf.
Resumo:In leprosy patients in Nigeria the influence of daily clofazimine and of once-monthly rifampicin on the pharmacokinetics of dapsone has been investigated. Three days after rifampicin the elimination half-life of dapsone was reduced from 40.4 to 25.3 h (n = 23). Correspondingly, the plasma dapsone 24 h after the last dose had fallen significantly from 2.63 to 2.02 mg/l. Clofazimine did not cause change in the pharmacokinetics of dapsone. It was concluded that, although rifampicin had a considerable influence on the pharmacokinetics of dapsone, there is no reason to adjust the dose of dapsone during multidrug therapy of leprosy.(AU).
Descritores:CLOFAZIMINA/admin
CLOFAZIMINA/farmacol
HANSENIASE/sangue
HANSENIASE/quimioter
RIFAMPINA/admin
RIFAMPINA/farmacol
DAPSONA/admin
DAPSONA/sangue
DAPSONA/farmacocin
DAPSONA/uso terap
Limites:HUMANO
MASCULINO
FEMININO
ADULTO
MEIA-IDADE
IDOSO
ADOLESCENTE
Meio Eletrônico: - .
Localização:BR191.1; 02067/s


  19 / 41 HANSEN  
              first record previous record next record last record
seleciona
para imprimir
Id:17783
Autor:George, Joseph; Balakrishnan, S; Bhatia, V. N
Título:Drug interaction during multidrug regimens for treatment of leprosy
..-
Fonte:s.l; s.n; feb. 1988. 6 p. tab.
Resumo:The influence of concurrently rifampicin and clofazimine on the metabolism of 4,4'-diaminodiphenyl sulfone (dapsone, DDS) has been studied in 30 subjects on multidrug regimens for treatment of leprosy. Plasma and urinary levels of drugs were determined on days 2,8 and 15 after administration of the drug, while cretinine levels in urine were also determined to overcome the effect of diuresis. During concurrent administration of rifampicin the plasma levels of DDS gradually fell from day 2 to day 15 of rifampicin administration and the decrease was most significant on day 15. Clofazimine did not exert any such influence on DDS metabolism. A comparison of urine and plasma levels of DDS during the course of treatment. The findings suggest that during concurrent administration of DDS and rifampicin, the intake of DDS shoud be regular and uninterrupted.(AU).
Descritores:HANSENIASE/quimioter
QUIMIOTERAPIA COMBINADA
ESQUEMA DE MEDICACAO
DAPSONA/admin
DAPSONA/metab
INTERACOES DE MEDICAMENTOS
CLOFAZIMINA/uso terapeutico
RIFAMPINA/uso terapeutico
Limites:HUMANO
SUPPORT, NON-U.S. GOV'T
Meio Eletrônico: - .
Localização:BR191.1; 02088/s


  20 / 41 HANSEN  
              first record previous record
seleciona
para imprimir
Id:16324
Autor:Dhople, Arvind M
Título:In vivo activity of epiroprim, a dihydrofolate reductase inhibitor, singly and in combination with dapsone, against mycobacterium leprae
..-
Fonte:s.l; s.n; 2002. 4 p. tab.
Descritores:ADMINISTRAÇAO ORAL
TATUS
DAPSONA
DAPSONA
SINERGISMO DE DROGAS
ANTAGONISTAS DO ACIDO FOLICO
ANTAGONISTAS DO ACIDO FOLICO
LEPROSTATICOS
LEPROSTATICOS
CAMUNDONGOS
CAMUNDONGOS ENDOGAMICOS BALB C
MYCOBACTERIUM LEPRAE
MYCOBACTERIUM LEPRAE
TRIMETOPRIM
TRIMETOPRIM
TRIMETOPRIM
Limites:ANIMAL
Localização:BR191.1; 08715/s



página 1 de 3 ir para página          
   


Refinar a pesquisa
  Base de dados : HANSEN Formulário avançado   
Pesquisar por : Formulário livre   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6.1 powered by WWWISIS

BIREME/PAHO/WHO - Latin American and Caribbean Center on Health Sciences Information